Meningokok Aşıları

Yıl 2016, Cilt: 8 Sayı: 2, 3 - 10, 30.03.2016

Melahat Akdeniz , Nilgün Erkek

Öz

Meningokok hastalığı ciddi ve potansiyel olarak yaşamı tehdit edici bir infeksiyondur.

Tüm dünyada yüksek morbidite ve mortalite oranına sahiptir. Dünya Sağlık Örgütünün

“Sağlıklı kişiler 2020” hedefi meningokok hastalığının insidansını yüzbinde 0.3’e

düşürmektir. Aşılama menengokok hastalığını önlemede en başarılı ve maliyet etkin girişimdir.

Her yaş için mevcut etkili ve güvenilir aşılarla bu hedefe ulaşabiliriz

Anahtar Kelimeler

Menengokoksik hastalıklar, menengokoksik hastalıkları önleme, menengokok aşıları

Kaynakça

• 1. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369: 2196–210 2. Harrisona LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine, 2009; 27S:B51–B63. 3. Tzeng Y-L, Stephens DS. Epidemiology and pathogenesis of Neisseria Meningitidis. Microbes and Infection, 2000;2: 687−700 4. Ceyhan M, Anis S, Htun-Myint L, Pawinski R, Montse Soriano-Gabarro M, Vyse A. Meningococcal disease in the Middle East and North Africa: an important public health consideration that requires further attention. International Journal of Infectious Diseases 16 (2012) e574–e582 5. Memish ZA; Goubeaud A, Bröker M, Malerczyk C, Shibl AM. Invasive meningococcal disease and travel. Journal of Infection and Public Health (2010) 3, 143—151 6. Wang X, Shutt KA, Vuong JT, Cohn A et al. Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure. The Journal of Infectious Diseases. 2015:211:1887-1895 7. Ceyhan M. Epidemiyoloji, Meningokok İnfeksiyonları, Tanı, Tedavi ve Korunma kitabı içinde. Ed. Ceyhan M. Akademi Yayınevi, İstanbul, 2013 8. Christensen H, May M, Bowen L, Hickman M, Trotter CL: Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10: 853–61 9. Ceyhan M, Yildirim I, Balmer P, et al. A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis. 2008; 14:1089-1096. 10. Bamberger DM. Diagnosis, Initial Management, and Prevention of Meningitis. Am Fam Physician. 2010;82(12):1491-1498 11. Terranella A, Cohn A, Clark T. Meningococcal conjugate vaccines: optimizing global impact. Infection and Drug Resistance 2011:4 161–169 12. Gardner P. Prevention of meningococcal disease. New Engl J Med 2006; 355: 1466-1473 13. Dinleyici EÇ. Konjuge Meningokok ve Pnömokok Aşıları. Klinik Gelişim, 2012; 25: 21-29 14. Özdemir H, Çiftçi E. Meningokok aşıları. J Pediatr Inf. 2014;8:178-86. 15. WHO recommendations for rutine immunization – summary tables. Erişim: www.who.int/immunization/policy/immunization_tables/en/ Erişim tarihi: 09.01. 2016 16. Maiden MCJ, Ibarz-Pavon AB, Urvin R, Gray SJ et al. Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity. The Journal of Infectious Diseases 2008; 197:737– 43 17. Ramasamy NH, Clutterbuck EA, Haworth K, Bowman J et al. Randomized Clinical Trial To Evaluate the Immunogenicity of Quadrivalent Meningococcal Conjugate and Polysaccharide Vaccines in Adults in the United Kingdom. Clinical and Vaccine Immunology, 2014;21(8):1164–1168 18. Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med. 2011; 364: 2293-2304. 19. Cohn AC, Harrison LH. Meningococcal Vaccines: Current Issues and Future Strategies. Drugs, 2013;73:1147–1155. 20. Stafanelli P, fazio C, Neri A, Boros S et al. Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy,2006–2014. Vaccine, 2015;33:3678–3681 21. Gasparini R, Tregnaghi M, Keshavan P, Ypma E, Han L, Smolenoy I. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. Pediatr Infect Dis J 2016;35:81–93 10 www.kliniktipdergisi.com 22. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0Through 18 Years. Unıted States, 2016. Erişim: http://www.cdc.gov/vaccines/hcp/aciprecs/ index.html. Erişim tarihi: 09.02. 2016 23. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine. 2009; 27 Suppl 2: B30-41. 24. Block SL, Szenborn L, Daly W, Jackowska T et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Vaccine 2015;33:2500–2510 25. Block SL, Christensen S, Verma B, Xie F et al. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination. Vaccine, 2015;33:2175–2182 26. Centers for Disease Control and Prevention (CDC). Update: Guillain- Barré syndrome among recipients of Menactra meningococcal conjugate vaccine—United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. 2006; 55: 1120-1124. 27. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010; 59: 273. 28. Hedari CP, Khinkarly RW, Dbaibo GS. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infection and Drug Resistance 2014:7 85–99 29. Centers for Disease Control and Prevention (CDC). Licensure of a Meningococcal Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated Booster Dose Guidance for Adolescents and Other Persons at Increased Risk for Meningococcal Disease Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011; 60: 1018-9. 30. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299: 173–184. 31. Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine. 2010; 28: 657-63. 32. Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009; 28:86–91. 33. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine. 2009; 27: 161-168. 34. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine. 2010; 28:744-753. 35. Klein NP. Baine Y, Kolhe D, Baccarini CI, Miller J, Van der Wielen M. Five-Year Antibody Persistence and Booster Response Following One or Two Doses of Meningococcal A, C, W, and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children. Pediatric Infectious Disease Journal. 2015;34(8):865-874 36. Ishola D, Andrews N, Waight PBS, Yung, C-F et al. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age. Pediatr Infect Dis J. 2015;34(8):865-74. 37. Campos-Outcalt D. ACIP weighs in on meningococcal B vaccines. Journal Of Family Practice 2015;64(12):78-790 38. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608-612. 39. MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR. Patel M, Martin SW. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015 MMWR, 2015;64(41): 1171-1182. 40. Durmaz R. Türkiye’de Yeni Aşılarda Sürveyans. ANKEM Derg 2013;27(Ek 2):43-50 41. Watson PS, Turner DPJ. Clinical experience with the meningococcal B vaccine, Bexsero®: Prospects for reducing the burden of meningococcalserogroup B disease. Waccine, 2016: 10;34(7):875-80 42. Ernesto Oviedo-Ortaa, Sohail Ahmeda, Rino Rappuolia, Steven Black. Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines. Vaccine 2015;33:3628–3635